Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1006MR)

This product GTTS-WQ1006MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1006MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7215MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ1283MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ4300MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ6616MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ5100MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ13970MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ8908MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ6796MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW